Literature DB >> 29147602

GDNF secreted by nerves enhances PD-L1 expression via JAK2-STAT1 signaling activation in HNSCC.

Chengzhong Lin1,2, Wei Cao1,2, Zhenhu Ren1,2, Yu Tang1,2, Chunye Zhang3, Rong Yang1,2, Yiming Chen1,2, Zheqi Liu1,2, Canbang Peng1,2, Lizhen Wang3, Xu Wang1,2, Tong Ji1,2.   

Abstract

Programmed death ligand 1 (PD-L1) functions as a key immune inhibitory factor by binding with its receptor, programmed death 1 (PD-1), to induce immune cell dysfunction and escape of the immune system. However, the mechanisms of PD-L1 expression under growth factor stimulation are not well characterized. Here, we demonstrate a novel role for glial cell line-derived neurotrophic factor (GDNF) in upregulating PD-L1 expression in head and neck squamous cell carcinoma (HNSCC). The expression and correlation of PD-L1, GDNF and perineural invasion (PNI) status were evaluated by bioinformatics analysis of TCGA database and IHC assays from 145 HNSCC patients. PD-L1 expression was investigated by flow cytometry, Western blot and real-time PCR analyses in HNSCC cells after GNDF incubation. The cell signaling pathways activated by GDNF were analyzed with an antibody array and blocked by specific signaling inhibitors in cancer cell lines. PD-L1 expression was significantly higher in cancer cells that exhibited PNI in the HNSCC specimens, and elevated PD-L1 expression was significantly correlated with GDNF levels. GDNF not only enhanced cancer cell PNI in a co-culture of dorsal root ganglions and cancer cells but also had a potent role in inducing PD-L1 expression through the JAK2-STAT1 signaling pathway. Moreover, a JAK2 inhibitor attenuated GDNF-induced PD-L1 and enhanced tumor cell susceptibility to NK cell killing. Our findings provide clinically novel evidence that nerve-derived GDNF can increase PD-L1 levels in cancer cells around the perineural niche and that regulatory signaling is critical for cancer cell escape from immune surveillance in the nerve-cancer microenvironment.

Entities:  

Keywords:  GDNF; HNSCC; JAK2; PD-L1; PNI

Year:  2017        PMID: 29147602      PMCID: PMC5674951          DOI: 10.1080/2162402X.2017.1353860

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  40 in total

Review 1.  RET revisited: expanding the oncogenic portfolio.

Authors:  Lois M Mulligan
Journal:  Nat Rev Cancer       Date:  2014-03       Impact factor: 60.716

2.  Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors.

Authors:  Ludmila Danilova; Hao Wang; Joel Sunshine; Genevieve J Kaunitz; Tricia R Cottrell; Haiying Xu; Jessica Esandrio; Robert A Anders; Leslie Cope; Drew M Pardoll; Charles G Drake; Janis M Taube
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-11       Impact factor: 11.205

3.  GFRα1 released by nerves enhances cancer cell perineural invasion through GDNF-RET signaling.

Authors:  Shuangba He; Chun-Hao Chen; Natalya Chernichenko; Shizhi He; Richard L Bakst; Fernando Barajas; Sylvie Deborde; Peter J Allen; Efsevia Vakiani; Zhenkun Yu; Richard J Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-28       Impact factor: 11.205

4.  Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.

Authors:  Mohammad Atefi; Earl Avramis; Amanda Lassen; Deborah J L Wong; Lidia Robert; David Foulad; Michael Cerniglia; Bjoern Titz; Thinle Chodon; Thomas G Graeber; Begonya Comin-Anduix; Antoni Ribas
Journal:  Clin Cancer Res       Date:  2014-05-08       Impact factor: 12.531

5.  Perineural invasion and expression of nerve growth factor can predict the progression and prognosis of oral tongue squamous cell carcinoma.

Authors:  Wei-Ren Shen; Yi-Ping Wang; Julia Yu-Fong Chang; Shang-Yang Yu; Hsin-Ming Chen; Chun-Pin Chiang
Journal:  J Oral Pathol Med       Date:  2014-04       Impact factor: 4.253

6.  PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer.

Authors:  Cécile Badoual; Stéphane Hans; Nathalie Merillon; Cordélia Van Ryswick; Patrice Ravel; Nadine Benhamouda; Emeline Levionnois; Mevyn Nizard; Ali Si-Mohamed; Nicolas Besnier; Alain Gey; Rinat Rotem-Yehudar; Hélène Pere; Thi Tran; Coralie L Guerin; Anne Chauvat; Estelle Dransart; Cécile Alanio; Sebastien Albert; Beatrix Barry; Federico Sandoval; Françoise Quintin-Colonna; Patrick Bruneval; Wolf H Fridman; Francois M Lemoine; Stephane Oudard; Ludger Johannes; Daniel Olive; Daniel Brasnu; Eric Tartour
Journal:  Cancer Res       Date:  2012-11-07       Impact factor: 12.701

Review 7.  Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.

Authors:  Suzanne L Topalian; Janis M Taube; Robert A Anders; Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2016-04-15       Impact factor: 60.716

8.  Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression.

Authors:  Roberto Bellucci; Allison Martin; Davide Bommarito; Kathy Wang; Steen H Hansen; Gordon J Freeman; Jerome Ritz
Journal:  Oncoimmunology       Date:  2015-03-02       Impact factor: 8.110

9.  A covalently bound inhibitor triggers EZH2 degradation through CHIP-mediated ubiquitination.

Authors:  Xu Wang; Wei Cao; Jianjun Zhang; Ming Yan; Qin Xu; Xiangbing Wu; Lixin Wan; Zhiyuan Zhang; Chenping Zhang; Xing Qin; Meng Xiao; Dongxia Ye; Yuyang Liu; Zeguang Han; Shaomeng Wang; Li Mao; Wenyi Wei; Wantao Chen
Journal:  EMBO J       Date:  2017-03-20       Impact factor: 11.598

10.  A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis.

Authors:  A Pardanani; A Tefferi; C Jamieson; N Y Gabrail; C Lebedinsky; G Gao; F Liu; C Xu; H Cao; M Talpaz
Journal:  Blood Cancer J       Date:  2015-08-07       Impact factor: 11.037

View more
  9 in total

1.  STAT1 inhibits T-cell exhaustion and myeloid derived suppressor cell accumulation to promote antitumor immune responses in head and neck squamous cell carcinoma.

Authors:  Nathan Ryan; Kelvin Anderson; Greta Volpedo; Omar Hamza; Sanjay Varikuti; Abhay R Satoskar; Steve Oghumu
Journal:  Int J Cancer       Date:  2019-11-29       Impact factor: 7.396

2.  Oral Cancer: Integration of Studies for Diagnostic and Therapeutic Precision.

Authors:  N J D'Silva; J S Gutkind
Journal:  Adv Dent Res       Date:  2019-11

3.  Downregulation of hsa-microRNA-204-5p and identification of its potential regulatory network in non-small cell lung cancer: RT-qPCR, bioinformatic- and meta-analyses.

Authors:  Chang-Yu Liang; Zu-Yun Li; Ting-Qing Gan; Ye-Ying Fang; Bin-Liang Gan; Wen-Jie Chen; Yi-Wu Dang; Ke Shi; Zhen-Bo Feng; Gang Chen
Journal:  Respir Res       Date:  2020-02-26

4.  Cisplatin-induced programmed cell death ligand-2 expression is associated with metastasis ability in oral squamous cell carcinoma.

Authors:  Shunichi Sudo; Hiroshi Kajiya; Shinji Okano; Mina Sasaki; Yuri Katsumata; Jun Ohno; Tetsuro Ikebe; Akimitsu Hiraki; Koji Okabe
Journal:  Cancer Sci       Date:  2020-02-29       Impact factor: 6.716

5.  Intracellular Neuroprotective Mechanisms in Neuron-Glial Networks Mediated by Glial Cell Line-Derived Neurotrophic Factor.

Authors:  Еlena V Mitroshina; Tatiana A Mishchenko; Olesya M Shirokova; Tatiana A Astrakhanova; Maria M Loginova; Ekaterina A Epifanova; Alexey A Babaev; Victor S Tarabykin; Maria V Vedunova
Journal:  Oxid Med Cell Longev       Date:  2019-11-18       Impact factor: 6.543

6.  Targeting the JAK/STAT pathway in solid tumors.

Authors:  Zoya Qureshy; Daniel E Johnson; Jennifer R Grandis
Journal:  J Cancer Metastasis Treat       Date:  2020-08-21

Review 7.  Molecular and Cellular Mechanisms of Perineural Invasion in Oral Squamous Cell Carcinoma: Potential Targets for Therapeutic Intervention.

Authors:  Carly I Misztal; Carlos Green; Christine Mei; Rita Bhatia; Jaylou M Velez Torres; Brandon Kamrava; Seo Moon; Elizabeth Nicolli; Donald Weed; Zoukaa Sargi; Christine T Dinh
Journal:  Cancers (Basel)       Date:  2021-11-29       Impact factor: 6.639

8.  The role of Glial cell derived neurotrophic factor in head and neck cancer.

Authors:  Hongbin Cao; Qian He; Rie von Eyben; Joshua Bloomstein; Dhanya K Nambiar; Vignesh Viswanathan; Sonya Aggarwal; Shirley Kwok; Rachel Liang; Amanda Jeanette Koong; James S Lewis; Christina Kong; Nan Xiao; Quynh-Thu Le
Journal:  PLoS One       Date:  2020-02-21       Impact factor: 3.240

Review 9.  Chasing the Target: New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer. Updated Evidence and Future Perspectives.

Authors:  Sara Fancelli; Enrico Caliman; Francesca Mazzoni; Marco Brugia; Francesca Castiglione; Luca Voltolini; Serena Pillozzi; Lorenzo Antonuzzo
Journal:  Cancers (Basel)       Date:  2021-03-04       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.